• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

The global ischemic heart disease (IHD) drugs market is expected to grow at a CAGR of around 3% during 2020-2025. Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

Global Ischemic Heart Disease IHD Drugs Market

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Market Breakup by Disease Class

  • Angina Pectoris 
  • Myocardial Infarction

 

Market Breakup by Drug Class:

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents

 

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

 

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Actelion, Amgen Inc., AstraZeneca plc, Bayer AG, Baxter International Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eisai Co. Ltd., Eli Lilly, F.Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer Inc., and Sanofi S.A.

Key Questions Answered in This Report:

  • How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
  • What is the breakup of the market based on the disease class?
  • What is the breakup of the market based on the drug class?
  • What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
  • What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
  • What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
  • What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
  • What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Ischemic Heart Disease (IHD) Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Market Forecast
6    Market Breakup by Disease Class
    6.1    Angina Pectoris
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    Myocardial Infarction
        6.2.1    Market Trends
        6.2.2    Market Forecast
7    Market Breakup by Drug Class
    7.1    Anti-Dyslipidemic Drugs
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Calcium Channel Blockers
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Beta-Blockers
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    ACE Inhibitors
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    ARBs
        7.5.1    Market Trends
        7.5.2    Market Forecast
    7.6    Vasodilators
        7.6.1    Market Trends
        7.6.2    Market Forecast
    7.7    Antithrombotic Agents
        7.7.1    Market Trends
        7.7.2    Market Forecast
8    Market Breakup by Region
    8.1    North America
        8.1.1    Market Trends
        8.1.2    Market Forecast
    8.2    Europe
        8.2.1    Market Trends
        8.2.2    Market Forecast
    8.3    Asia Pacific
        8.3.1    Market Trends
        8.3.2    Market Forecast
    8.4    Middle East and Africa
        8.4.1    Market Trends
        8.4.2    Market Forecast
    8.5    Latin America
        8.5.1    Market Trends
        8.5.2    Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Actelion  
        13.3.2    Amgen Inc.   
        13.3.3    AstraZeneca plc 
        13.3.4    Baxter International Inc. 
        13.3.5    Bayer AG 
        13.3.6    Boehringer Ingelheim.
        13.3.7    Bristol-Myers Squibb 
        13.3.8    Eisai Co., Ltd.  
        13.3.9    Eli Lilly 
        13.3.10   F.Hoffmann-La Roche     
        13.3.11   GlaxoSmithKline    
        13.3.12   Merck    
        13.3.13   Novartis   
        13.3.14   Pfizer Inc.     
        13.3.15   Sanofi S.A   


List of Figures
Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2014 & 2019
Figure 3: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2020-2025
Figure 4: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2014 & 2019
Figure 5: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 6: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2014 & 2019
Figure 7: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 8: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2014 & 2019
Figure 9: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 10: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2014 & 2019
Figure 11: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 12: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2014 & 2019
Figure 13: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 14: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2014 & 2019
Figure 15: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 16: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2014 & 2019
Figure 17: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 18: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2014 & 2019
Figure 19: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 20: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2014 & 2019
Figure 21: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 22: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 23: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 24: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 25: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 26: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 27: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 28: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 29: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 30: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 31: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 32: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
Figure 33: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
Figure 34: Global: Ischemic Heart Disease Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2019 and 2025
Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2020-2025
Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2020-2025
Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2020-2025
Table 5: Global: Ischemic Heart Disease Drugs Market Structure
Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 1999

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links